Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PROGENICS PHARMACEUTICALS INCPGNX · Entity 148291 | Director | July 11, 2019 | July 15, 2019 |
| SELLAS Life Sciences Group, Inc.SLS · Entity 4313 | Director | January 07, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PROGENICS PHARMACEUTICALS INC
Report date July 11, 2019 · Filed July 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.74 · Expires 2029-07-11 | Direct | 25,000 |
Reported balance
After 2019-07-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-11 · Grant · Acquired 25,000 · Balance 25,000 F1: The stock options become exercisable in 12 monthly installments, commencing one month from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options become exercisable in 12 monthly installments, commencing one month from the grant date.
SELLAS Life Sciences Group, Inc.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,082 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 50,000 · Balance 73,082 F1: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2026 Filed Jan 9, 2026 16:38 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-002509 · tm262627-5_4seq1.xml · nonDerivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,082 F1 · shares: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 17:34 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001104659-25-003499 · tm253166-6_4seq1.xml · derivative · entry 2 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2035-01-10 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) January 10, 2026 (the first anniversary of the date of grant) or (y) the business day prior to the 2026 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 17:34 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003499 · tm253166-6_4seq1.xml · nonDerivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,082 F1 · shares: The Reporting Person received an award of 12,500 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 06:03 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001104659-24-006407 · tm243935-4_4seq1.xml · derivative · entry 2 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-01-22 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) January 22, 2025 (the first anniversary of the date of grant) or (y) the business day prior to the 2025 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 06:03 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-006407 · tm243935-4_4seq1.xml · nonDerivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,582 F1 · shares: The Reporting Person received an award of 6,000 restricted stock units on January 22, 2024, which shall vest in full on December 1, 2024, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 17:11 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0001104659-23-010619 · tm235353d2_4seq1.xml · derivative · entry 2 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2033-02-02 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) February 2, 2024 (the first anniversary of the date of grant) or (y) the business day prior to the 2024 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 17:11 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-010619 · tm235353d2_4seq1.xml · nonDerivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,582 F1 · shares: The Reporting Person received an award of 2,500 restricted stock units on February 2, 2023, which shall vest in full on December 1, 2023, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 17:05 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 7,125 | $0.00 Strike: $5.34 | $0.00 |
DisclosureSEC source: 0001104659-22-010393 · tm225088-2_4seq1.xml · derivative · entry 2 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125 Underlying: Common Stock · 7,125 shares Expires 2032-01-31 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) January 31, 2023 (the first anniversary of the date of grant) or (y) the business day prior to the 2023 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 17:05 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 1,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-010393 · tm225088-2_4seq1.xml · nonDerivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,082 F1 · shares: The Reporting Person received an award of 1,900 restricted stock units on January 31, 2022, which shall vest in full on December 1, 2022, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:30 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001104659-21-033301 · tm218923d7_4.xml · derivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-03-04 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) March 4, 2022 (the first anniversary of the date of grant) or (y) the business day prior to the 2022 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:18 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001104659-20-034285 · tm2012902-2_form4.xml · derivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2030-03-12 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) March 12, 2021 (the first anniversary of the date of grant) or (y) the business day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 09:02 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.74 | $0.00 |
DisclosureSEC source: 0001562180-19-003935 · primarydocument.xml · derivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-07-11 F1 · derivative.exercise_date: The stock options become exercisable in 12 monthly installments, commencing one month from the grant date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 08:56 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001562180-19-003828 · primarydocument.xml · derivative · entry 2 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 08:56 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | Exercise / conversionCommon Stock | 10,000 | $5.33 | $53,300.00 |
DisclosureSEC source: 0001562180-19-003828 · primarydocument.xml · nonDerivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 19:04 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0000899243-19-008207 · doc4.xml · derivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-03-14 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) March 14, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 14:37 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001562180-18-002997 · primarydocument.xml · derivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: This stock option becomes exercisable immediately on the date of grant. Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 18:34 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 5,500 | $0.00 Strike: $5.23 | $0.00 |
DisclosureSEC source: 0001209191-18-037555 · doc4.xml · derivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2028-06-11 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) June 12, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:00 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.24 | $0.00 |
DisclosureSEC source: 0001209191-18-020018 · doc4.xml · derivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: The option shares will vest and became exercisable in equal monthly installments for thirty-six (36) months following the March 13, 2018 grant date, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:11 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 9,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067659 · doc4.xml · nonDerivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,107 F1 · price: In connection with the merger of SELLAS Life Sciences Group, Ltd ("SELLAS") and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"), outstanding restricted stock units ("RSUs") to be settled in SELLAS common shares were assumed by the Issuer and will be settled in shares of the Issuer's common stock based on the following exchange ratio: 43.9972 shares of the Issuer's common stock for each common share of SELLAS. F2 · balance_after: Represents shares issuable upon vesting of RSUs. 100% of the shares subject to the RSUs will vest on February 27, 2018. Read SEC document |
| December 29, 2017 Filed Mar 16, 2018 16:31 UTC Amendment | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 9,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-020187 · doc4a.xml · nonDerivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,107 F1 · price: In connection with the merger of SELLAS Life Sciences Group, Ltd ("SELLAS") and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"), outstanding restricted stock units ("RSUs") to be settled in SELLAS common shares were assumed by the Issuer and will be settled in shares of the Issuer's common stock based on the following exchange ratio: 43.9972 shares of the Issuer's common stock for each common share of SELLAS. F2 · balance_after: Represents shares issuable upon vesting of RSUs. The RSUs are subject to, and to vest must satisfy, both (a) performance-based vesting restrictions (the RSUs will satisfy the performance-based vesting restrictions upon a liquidity event as defined in the award agreement) and (b) time-based vesting restrictions (100% of the RSUs satisfied the time-based vesting restrictions on February 27, 2018). The Merger did not constitute a liquidity event for the performance-based vesting restrictions. Read SEC document |
| June 14, 2017 Filed Jun 15, 2017 15:09 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.95 | $0.00 |
DisclosureSEC source: 0001562180-17-002268 · primarydocument.xml · derivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: This stock option becomes exercisable immediately, on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.